MedGenome Expands Its NGS Capabilities and Forays Into Single-Cell Sequencing

FOSTER CITY, Calif., Jan. 31, 2018 /PRNewswire/ -- MedGenome has expanded its sequencing capacity at its Foster City, Calif., headquarters laboratory, adding HiSeqX and NovaSeq 6000 platforms to meet the rising demands for Next Generation Sequencing (NGS) in research and clinical settings. The new additions increase MedGenome's data-generation capability by a factor of five. Additionally, availability of a wide range of sequencing platforms gives MedGenome the flexibility to provide customized services at scale – thousands of whole genomes a month -- and deliver high-quality data quickly at a competitive price. The NGS lab has also added sample-processing automation from Agilent to support the sequencing capacity.

"Adding the new platforms in our California lab gives us the throughput and scale to take on large genomic projects that are rapidly transforming the clinical trial landscape by enabling precision medicine and personalized therapy particularly in immuno-oncology, neurological disorders and rare diseases," said Sam Santhosh, founder, chairman and global CEO of MedGenome. "Our ability to deliver high-quality data for large-scale genomics projects in a timely manner helps our clients to accelerate their preclinical and clinical research programs."

To capture the power of single-cell sequencing, MedGenome has started the Chromium™ Genome Solution from 10X Genomics, for use in multiple applications, including whole-genome phasing and structural-variant analysis, de novo genome assembly, remapping of difficult regions of the genome, and dynamic gene expression of single cells. The new platform allows deconstruction of complex tissue microenvironments at single-cell resolution, which enables biomarker discoveries in the area of cancer immunotherapy.  

About MedGenome

MedGenome, Inc., is a global genomics-based diagnostics and research company with over 400 employees dedicated to partnering with pharma companies and research institutions so that they can deliver the best of health care by decoding genetic information contained in an individual's genome. Our footprint includes laboratories in the United States, Singapore and India. We are the market leader in genomics-based diagnostics and research in India.  We are rapidly expanding our U.S.-based research services operations from our next-generation sequencing lab and headquarters in Foster City, Calif.

Our mission is to improve global health by developing deep insights into diseases at the genetic and molecular levels. Our research services solutions apply cutting-edge genomics technologies, bioinformatics, computing and big data analytics to understand the genetic basis of cancer and other major diseases. Our powerful genomics solutions accelerate biomarker identification and discovery research by pharma/biotech companies and academic research institutions. MedGenome is uniquely able to leverage the genetic information from diverse and large populations of South Asia to help answer questions on complex human diseases.

Media Contacts:

Hiran G. H., MedGenome
[email protected]

Sandy Levy, Gutenberg
[email protected]

SOURCE MedGenome